Heptares to Present at BIO-Europe 2012
WELWYN GARDEN CITY, England and BOSTON, November 8, 2012 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, announces that its Chief Executive Officer, Malcolm Weir, will present the Company at BIO-Europe 2012, the international partnering conference, which takes place at the CCH Congress Center, Hamburg, Germany (12-14 November 2012).
Dr Weir's presentation will be at 2:15pm (CET)on Tuesday 13 November in Room B1, Level 1.
About Heptares Therapeutics
Heptares discovers and develops new medicines targeting GPCRs (Gprotein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune and Takeda, and we have raised $40M from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.
Heptares is pioneering the application of structure-based drug design to the GPCR super-family of targets and is focused on creating molecules that modulate high-value, yet historically undruggable or challenging, GPCRs. Our platform incorporates proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time.
Using this approach, we have generated a broad pipeline of drug candidates for the treatment of serious disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression, chronic insomnia, addiction disorders, migraine and diabetes. For more information about Heptares, please visit http://www.heptares.com.
SOURCE Heptares Therapeutics
Mer från detta företag
Heptares Orphan Disease Programme Awarded Grant from the UK Biomedical Catalyst
20 Nov, 2014, 16:16 CET
Skapa innehåll för din webbplats
Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
Kontakta PR Newswire
Skicka oss ett mail till firstname.lastname@example.org eller ring oss på +46 (0)8 1200 1300
Bli en PR Newswire kund
Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)8 1200 1300